This trial is for people who have gotten ocrelizumab in a previous study and are continuing treatment or in a follow-up phase.
- Multiple Sclerosis
1 Primary · 5 Secondary · Reporting Duration: Up to 44 months
Side Effects for
1 Treatment Group
1 of 1
1300 Total Participants · 1 Treatment Group
Primary Treatment: Ocrelizumab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Why did patients apply to this trial?
- "I have multiple sclerosis"
How many prior treatments have patients received?
Frequently Asked Questions
What are the chances of negative side effects from Ocrelizumab?
"The available evidence suggests that Ocrelizumab is safe to use, so it received a score of 3." - Anonymous Online Contributor
How many different hospitals are testing this new medication?
"This trial is currently underway at 31 locations, including Hope Research Institute in Phoenix, MultiCare Health System Institute for Research and Innovation in Tacoma, and SUNY at Stony Brook in Stony Brook." - Anonymous Online Contributor
When will recruitment for this research project be completed?
"The sponsor, Hoffmann-La Roche, needs to recruit 1300 eligible patients from various locations, including Hope Research Institute in Phoenix, Arizona and MultiCare Health System Institute for Research and Innovation in Tacoma, Washington." - Anonymous Online Contributor
Are people still allowed to sign up for this experiment?
"Yes, this trial is still looking for participants. The information on clinicaltrials.gov shows that the trial was posted on 5/3/2022 and was last updated on 10/17/2022. They are looking for 1300 people to participate at 31 different locations." - Anonymous Online Contributor